LYSOSOMAL ACID LIPASE A MODULATES LEUKEMIA STEM CELL RESPONSE TO VENETOCLAX/TYROSINE KINASE INHIBITOR COMBINATION THERAPY IN BLAST PHASE CHRONIC MYELOID LEUKEMIA

Lysosomal acid lipase A modulates leukemia stem cell response to venetoclax/tyrosine kinase inhibitor combination therapy in blast phase chronic myeloid leukemia

The treatment of blast phase chronic myeloid leukemia (bpCML) remains a challenge due at least in part to drug chicago cubs earrings resistance of leukemia stem cells (LSCs).Recent clinical evidence suggests that the BCL-2 inhibitor venetoclax in combination with ABL-targeting tyrosine kinase inhibitors (TKIs) can eradicate bpCML LSCs.In this repor

read more

Randomized controlled trial of molnupiravir SARS-CoV-2 viral and antibody response in at-risk adult outpatients

Abstract Viral clearance, antibody response and the mutagenic effect of molnupiravir has not been elucidated in at-risk populations.Non-hospitalised participants within 5 days of SARS-CoV-2 symptoms randomised to receive molnupiravir (n = 253) or Usual Care (n = 324) were kicker pro comp 10 recruited to study viral and antibody dynamics and the eff

read more